Page last updated: 2024-11-08

dimethylphenylpiperazinium iodide and Glioma

dimethylphenylpiperazinium iodide has been researched along with Glioma in 1 studies

Dimethylphenylpiperazinium Iodide: A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction.

Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
He, YQ1
Li, Y1
Wang, XY1
He, XD1
Jun, L1
Chuai, M1
Lee, KK1
Wang, J1
Wang, LJ1
Yang, X1

Other Studies

1 other study available for dimethylphenylpiperazinium iodide and Glioma

ArticleYear
Dimethyl phenyl piperazine iodide (DMPP) induces glioma regression by inhibiting angiogenesis.
    Experimental cell research, 2014, Jan-15, Volume: 320, Issue:2

    Topics: Animals; Cell Proliferation; Cell Survival; Chick Embryo; Dimethylphenylpiperazinium Iodide; Glioma;

2014